Akero Therapeutics Statistics Share Statistics Akero Therapeutics has 79.72M
shares outstanding. The number of shares has increased by 14.82%
in one year.
Shares Outstanding 79.72M Shares Change (YoY) 14.82% Shares Change (QoQ) 0.12% Owned by Institutions (%) 99.99% Shares Floating 71.78M Failed to Deliver (FTD) Shares 68 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 8.16M, so 10.24% of the outstanding
shares have been sold short.
Short Interest 8.16M Short % of Shares Out 10.24% Short % of Float 10.54% Short Ratio (days to cover) 8.84
Valuation Ratios The PE ratio is -7.41 and the forward
PE ratio is -11.46.
Akero Therapeutics's PEG ratio is
-0.25.
PE Ratio -7.41 Forward PE -11.46 PS Ratio 0 Forward PS 1193.9 PB Ratio 2.49 P/FCF Ratio -8.12 PEG Ratio -0.25
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Akero Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 19.38,
with a Debt / Equity ratio of 0.05.
Current Ratio 19.38 Quick Ratio 19.38 Debt / Equity 0.05 Debt / EBITDA -0.13 Debt / FCF -0.16 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-3.65M Employee Count 69 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 99.75% in the
last 52 weeks. The beta is -0.28, so Akero Therapeutics's
price volatility has been lower than the market average.
Beta -0.28 52-Week Price Change 99.75% 50-Day Moving Average 52.15 200-Day Moving Average 41.58 Relative Strength Index (RSI) 49.27 Average Volume (20 Days) 1,568,069
Income Statement
Revenue n/a Gross Profit n/a Operating Income -285.42M Net Income -252.06M EBITDA -285.42M EBIT -256.73M Earnings Per Share (EPS) -3.75
Full Income Statement Balance Sheet The company has 340.24M in cash and 36.46M in
debt, giving a net cash position of 303.78M.
Cash & Cash Equivalents 340.24M Total Debt 36.46M Net Cash 303.78M Retained Earnings -826.16M Total Assets 1.16B Working Capital 670.71M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -230.11M
and capital expenditures 0, giving a free cash flow of -230.11M.
Operating Cash Flow -230.11M Capital Expenditures n/a Free Cash Flow -230.11M FCF Per Share -3.43
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
